| Sustainable care for children with cancer: a Lancet Oncology Commission R Atun, N Bhakta, A Denburg, AL Frazier, P Friedrich, S Gupta, CG Lam, ... The Lancet Oncology 21 (4), e185-e224, 2020 | 241 | 2020 |
| Global childhood cancer survival estimates and priority-setting: a simulation-based analysis ZJ Ward, JM Yeh, N Bhakta, AL Frazier, F Girardi, R Atun The Lancet Oncology 20 (7), 972-983, 2019 | 199 | 2019 |
| Worldwide trends in survival from common childhood brain tumors: a systematic review F Girardi, C Allemani, MP Coleman Journal of global oncology 5, 1-25, 2019 | 70 | 2019 |
| Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies F Girardi, E Franceschi, AA Brandes The oncologist 15 (7), 683-694, 2010 | 54 | 2010 |
| Colorectal cancer incidence among young adults in England: trends by anatomical sub-site and deprivation A Exarchakou, LJ Donaldson, F Girardi, MP Coleman PLoS One 14 (12), e0225547, 2019 | 42 | 2019 |
| Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of … N Ssenyonga, C Stiller, K Nakata, J Shalkow, S Redmond, JL Bulliard, ... The Lancet Child & Adolescent Health 6 (6), 409-431, 2022 | 35 | 2022 |
| Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomized trials V Guarneri, G Griguolo, F Miglietta, PF Conte, MV Dieci, F Girardi ESMO open 7 (2), 100433, 2022 | 34* | 2022 |
| The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3) F Girardi, B Rous, CA Stiller, G Gatta, N Fersht, HH Storm, JR Rodrigues, ... Neuro-oncology 23 (10), 1765-1776, 2021 | 28 | 2021 |
| Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial V Guarneri, MV Dieci, G Griguolo, F Miglietta, F Girardi, G Bisagni, ... European Journal of Cancer 153, 133-141, 2021 | 28 | 2021 |
| Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000–2014 in 59 countries … V Di Carlo, CA Stiller, N Eisemann, A Bordoni, M Matz, MP Curado, ... British journal of dermatology 187 (3), 364-380, 2022 | 25 | 2022 |
| Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study F Girardi, DR Barnes, D Barrowdale, D Frost, AF Brady, C Miller, ... Genetics in medicine 20 (12), 1575-1582, 2018 | 24 | 2018 |
| Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3) F Girardi, M Matz, C Stiller, H You, R Marcos Gragera, MY Valkov, ... Neuro-oncology 25 (3), 580-592, 2023 | 22 | 2023 |
| Global survival trends for brain tumors, by histology: Analysis of individual records for 67,776 children diagnosed in 61 countries during 2000–2014 (CONCORD-3) F Girardi, V Di Carlo, C Stiller, G Gatta, RR Woods, O Visser, B Lacour, ... Neuro-oncology 25 (3), 593-606, 2023 | 12 | 2023 |
| Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3) V Di Carlo, J Estève, C Johnson, F Girardi, HK Weir, RJ Wilson, ... JNCI cancer spectrum 4 (6), pkaa078, 2020 | 9 | 2020 |
| Global trends in survival from astrocytic tumours in adolescents and young adults: a systematic review F Girardi, C Allemani, MP Coleman JNCI Cancer Spectrum 4 (5), pkaa049, 2020 | 8 | 2020 |
| Bevacizumab in brain tumors: ready for primetime? E Franceschi, A Tosoni, F Girardi, AA Brandes Future oncology 5 (8), 1183-1184, 2009 | 7 | 2009 |
| Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases M Bottosso, G Griguolo, L Sinoquet, MC Guarascio, V Aldegheri, ... British Journal of Cancer 128 (7), 1286-1293, 2023 | 5 | 2023 |
| Pegylated liposomal doxorubicin for adjuvant treatment of breast cancer in patients refusing therapy with conventional doxorubicin. P Manente, G Vicario, G Sgarbossa, F Girardi, M Bortolin, E Scelzi, ... Journal of Clinical Oncology 28 (15_suppl), e11097-e11097, 2010 | 5 | 2010 |
| A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer F Miglietta, M Ragazzi, B Fernandes, G Griguolo, D Massa, F Girardi, ... Clinical Cancer Research 29 (17), 3429-3437, 2023 | 4 | 2023 |
| Epidemiology trends and progress in breast cancer survival: earlier diagnosis, new therapeutics O Amato, V Guarneri, F Girardi Current Opinion in Oncology 35 (6), 612-619, 2023 | 3 | 2023 |
